Almirall Aktie

11,34 EUR +0,06 EUR +0,53 %

17:13:02

STU

11,46 EUR +0,06 EUR +0,53 %

17:50:06

GVIE

Almirall jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.2,49 Mrd. EUR

KGV171,56Div. Rendite1,81%

WKNA0MU8Y

ISINES0157097017

SymbolLBTSF

Almirall Aktien News

Sortieren:Datum Meistgelesen

11.11.24BusinesswireAlmirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

15.10.24BusinesswireAlmirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

25.09.24BusinesswireNew Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

WerbungAlmirall-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

23.09.24BusinesswireAlmirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

10.07.24BusinesswireNICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults

02.07.24BusinesswireAlmirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

28.06.24BusinesswireAlmirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1

13.05.24BusinesswireAlmirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio

13.03.24BusinesswireAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

19.02.24BusinesswireAlmirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

19.02.24BusinesswireAlmirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business

21.12.23BusinesswireAlmirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

12.12.23BusinesswireAlmirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology

17.11.23BusinesswireAlmirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis

14.11.23BusinesswireAlmirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

09.11.23BusinesswireAlmirall’s Nine-month 2023 Results:

20.10.23BusinesswireAlmirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

13.10.23BusinesswireAlmirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1

11.10.23BusinesswireAlmirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

15.09.23BusinesswireEBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis

24.07.23BusinesswireAlmirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business

07.07.23BusinesswireAlmirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis

20.06.23BusinesswireAlmirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing

13.06.23BusinesswireAlmirall announces the pricing and closing of its €200mm non pre-emptive share capital increase

12.06.23BusinesswireAlmirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase

08.05.23BusinesswireAlmirall’s First Quarter 2023 Results

01.05.23BusinesswireAlmirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

12.04.23BusinesswireAlmirall, The First to Assess Wellbeing in a Dermatology Clinical Study

20.02.23BusinesswireAlmirall’s Full-Year 2022 Results

04.01.23BusinesswireAlmirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference

28.11.22BusinesswireAlmirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

10.11.22BusinesswireAlmirall’s Nine-month 2022 Results

08.11.22PR NewswireAlmirall opens a new subsidiary for the Czech Republic and Slovakia

28.10.22PR NewswireAlmirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis

Almirall News

Almirall News: auf dieser Seite finden Sie alle Almirall News und Nachrichten zur Almirall Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Almirall News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Almirall News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.